Complementary and alternative medicine for the treatment of multiple sclerosis

References

• Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple sclerosis. N. Engl. J. Med.343, 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci.206, 165–171 (2003).
   PubMed Web of Science ®Google Scholar
• Prat A, Al-Asmi A, Duquette P, Antel JP. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann. Neurol.46, 253–256 (1999).
   PubMedGoogle Scholar
• Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol.12, 309–321 (1999).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Menne C, Lauritsen JP et al. Ligand-induced TCR down-regulation is not dependent on constitutive TCR cycling. J. Immunol.168, 5434–5440 (2002).
   PubMedGoogle Scholar
• Rieckmann P, Altenhofen B, Riegel A, Kallmann B, Felgenhauer K. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Mult. Scler.4, 178–182 (1998).
   PubMed Web of Science ®Google Scholar
• Khoury SJ, Orav EJ, Guttmann CR, Kikinis R, Jolesz FA, Weiner HL. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology53, 758–764 (1999).
   PubMedGoogle Scholar
• Giovannoni G, Miller DH, Losseff NA et al. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J. Neurol.248, 487–495 (2001).
   PubMedGoogle Scholar
• Liuzzi GM, Trojano M, Fanelli M et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult. Scler.8, 222–228 (2002).
   PubMedGoogle Scholar
• Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev.36, 249–257 (2001).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol.107, 140–147 (2002).
   Google Scholar
• Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol.94, 1–14 (1999).
   PubMed Web of Science ®Google Scholar
• Madri JA, Graesser D. Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev. Immunol.7, 103–116 (2000).
   PubMedGoogle Scholar
• Trojano M, Avolio C, Liuzzi GM et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS. Neurology53, 1402–1408 (1999).
   PubMed Web of Science ®Google Scholar
• Waubant E, Goodkin DE, Gee L et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology53, 1397–1401 (1999).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Nuttall RK, Duddy M et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain126, 2738–2749 (2003).
   PubMed Web of Science ®Google Scholar
• Leppert D, Ford J, Stabler G et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain121(Pt 12), 2327–2334 (1998).
   PubMed Web of Science ®Google Scholar
• Misu T, Fujihara K, Itoyama Y. [Chemokines and chemokine receptors in multiple sclerosis]. Nippon Rinsho61, 1422–1427 (2003).
   PubMedGoogle Scholar
• Hartung HP, Archelos JJ, Zielaset J et al. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology45, S22–S32 (1995).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch. Neurol.49, 265–270 (1992).
   PubMedGoogle Scholar
• Sharief MK, Hentges R. Association between tumor necrosis factor-a and disease progression in patients with multiple sclerosis. N. Engl. J. Med.325, 467–472 (1991).
   PubMed Web of Science ®Google Scholar
• Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology40, 1735–1739 (1990).
   PubMed Web of Science ®Google Scholar
• Trotter JL, Collins KG, van der Veen RC. Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-α levels. J. Neuroimmunol.33, 29–36 (1991).
   PubMed Web of Science ®Google Scholar
• Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med.170, 607–612 (1989).
   PubMed Web of Science ®Google Scholar
• Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest.105, 967–976 (2000).
   PubMed Web of Science ®Google Scholar
• Miller A, Shapiro S, Gershtein R et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol.92, 113–121 (1998).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Farina C, Yassouridis A et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl Acad. Sci. USA97, 7452–7457 (2000).
   PubMed Web of Science ®Google Scholar
• Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci.21, 75–80 (1998).
   PubMed Web of Science ®Google Scholar
• Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon β-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol.40, 846–852 (1996).
   PubMed Web of Science ®Google Scholar
• Stuve O, Dooley NP, Uhm JH et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol.40, 853–863 (1996).
   PubMed Web of Science ®Google Scholar
• Berkman C, Pignotti M, Cavallo P, Holland N. Use of alternative treatments by people with multiple sclerosis. Neurorehabil. Neural Repair13, 243–254 (1999).
   Google Scholar
• Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? Complement. Ther. Med.17, 216–223 (2009).
   PubMed Web of Science ®Google Scholar
• Marrie RA, Hadjimichael O, Vollmer T. Predictors of alternative medicine use by multiple sclerosis patients. Mult. Scler.9, 461–466 (2003).
   PubMed Web of Science ®Google Scholar
• Nayak S, Matheis RJ, Schoenberger NE, Shiflett SC. Use of unconventional therapies by individuals with multiple sclerosis. Clin. Rehabil.17, 181–191 (2003).
   PubMed Web of Science ®Google Scholar
• Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. The use of complementary and alternative therapies by people with multiple sclerosis. Chronic Dis. Can.24, 75–79 (2003).
   PubMedGoogle Scholar
• Schwartz CE, Laitin E, Brotman S, LaRocca N. Utilization of unconventional treatments by persons with MS: is it alternative or complementary? Neurology52, 626–629 (1999).
   PubMed Web of Science ®Google Scholar
• Schwarz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Mult. Scler.14, 1113–1119 (2008).
   PubMed Web of Science ®Google Scholar
• Stuifbergen AK, Harrison TC. Complementary and alternative therapy use in persons with multiple sclerosis. Rehabil. Nurs.28, 141–147, 158 (2003).
   PubMedGoogle Scholar
• Yadav V, Shinto L, Morris C, Senders A, Baldauf-Wagner S, Bourdette D. Use and self reported benefit of complementary and alternative medicine (CAM) among multiple sclerosis patients. Int. J. MS Care8, 5–10 (2006).
   Google Scholar
• Shinto L, Yadav V, Morris C, Lapidus JA, Senders A, Bourdette D. Demographic and health-related factors associated with complementary and alternative medicine (CAM) use in multiple sclerosis. Mult. Scler.12, 94–100 (2006).
   PubMedGoogle Scholar
• Shinto L, Yadav V, Morris C, Lapidus JA, Senders A, Bourdette D. The perceived benefit and satisfaction from conventional and complementary and alternative medicine (CAM) in people with multiple sclerosis. Complement. Ther. Med.13, 264–272 (2005).
   PubMed Web of Science ®Google Scholar
• Fetterman JW Jr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am. J. Health Syst. Pharm.66, 1169–1179 (2009).
   PubMed Web of Science ®Google Scholar
• Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr.83, 1467S–1476S (2006).
   PubMed Web of Science ®Google Scholar
• Lim SY, Suzuki H. Effect of dietary docosahexaenoic acid and phosphatidylcholine on maze behavior and fatty acid composition of plasma and brain lipids in mice. Int. J. Vitam. Nutr. Res.70, 251–259 (2000).
   PubMed Web of Science ®Google Scholar
• Tinoco J. Dietary requirements and functions of α-linolenic acid in animals. Prog. Lipid Res.21, 1–45 (1982).
   PubMed Web of Science ®Google Scholar
• Calder PC. Dietary modification of inflammation with lipids. Proc. Nutr. Soc.61, 345–358 (2002).
   PubMed Web of Science ®Google Scholar
• Gallai V, Sarchielli P, Trequattrini A et al. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J. Neuroimmunol.56, 143–153 (1995).
   PubMed Web of Science ®Google Scholar
• Shinto L, Marracci G, Baldauf-Wagner S et al. Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot. Essent. Fatty Acids80, 131–136 (2009).
   PubMed Web of Science ®Google Scholar
• St-Pierre Y, Van Themsche C, Esteve PO. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr. Drug Targets Inflamm. Allergy2, 206–215 (2003).
   PubMedGoogle Scholar
• Zhao G, Etherton TD, Martin KR et al. Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. Biochem. Biophys. Res. Commun.336, 909–917 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen LH. Eicosapentaenoic acid prevents lipopolysaccharide-stimulated DNA binding of activator protein-1 and c-Jun N-terminal kinase activity. J. Nutr. Biochem.16, 78–84 (2005).
   PubMed Web of Science ®Google Scholar
• Bates D, Cartlidge N, French JM et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry52, 18–22 (1989).
   PubMed Web of Science ®Google Scholar
• Shinto L, Calabrese C, Morris C et al. A randomized pilot study of naturopathic medicine in multiple sclerosis. J. Altern. Complement. Med.14, 489–496 (2008).
   PubMed Web of Science ®Google Scholar
• PDR for Nutritional Supplements (First Edition). Hendler SS, Rorvik D (Eds). Thomson Healthcare, NJ, USA (2001).
   Google Scholar
• Peter G, Borbe HO. Absorption of [7,8–14C]rac-a-lipoic acid from in situ ligated segments of the gastrointestinal tract of the rat. Arzneimittelforschung45, 293–299 (1985).
   Google Scholar
• Harrison EH, McCormick DB. The metabolism of dl-(1,6–14C) lipoic acid in the rat. Arch. Biochem. Biophys.160, 514–522 (1974).
   PubMed Web of Science ®Google Scholar
• Packer L, Roy S, Sen CK. a-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv. Pharmacol.38, 79–101 (1997).
   PubMedGoogle Scholar
• Biewenga GP, Dorstijn MA, Verhagen JV, Haenen GR, Bast A. Reduction of lipoic acid by lipoamide dehydrogenase. Biochem. Pharmacol.51, 233–238 (1996).
   PubMedGoogle Scholar
• Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol.29, 315–331 (1997).
   PubMedGoogle Scholar
• Arner ES, Nordberg J, Holmgren A. Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem. Biophys. Res. Commun.225, 268–274 (1996).
   PubMed Web of Science ®Google Scholar
• Pick U, Haramaki N, Constantinescu A, Handelman GJ, Tritschler HJ, Packer L. Glutathione reductase and lipoamide dehydrogenase have opposite stereospecificities for α-lipoic acid enantiomers. Biochem. Biophys. Res. Commun.206, 724–730 (1995).
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature356, 63–66 (1992).
   PubMed Web of Science ®Google Scholar
• Tubridy N, Behan PO, Capildeo R et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology53, 466–472 (1999).
   PubMed Web of Science ®Google Scholar
• Marracci GH, Jones RE, McKeon GP, Bourdette DN. α lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol.131, 104–114 (2002).
   PubMed Web of Science ®Google Scholar
• Morini M, Roccatagliata L, Dell’Eva R et al. α-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol.148, 146–153 (2004).
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Musters RJ, Reijerkerk A et al. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood–brain barrier integrity. J. Immunol.177, 2630–2637 (2006).
   PubMed Web of Science ®Google Scholar
• Marracci GH, McKeon GP, Marquardt WE, Winter RW, Riscoe MK, Bourdette DN. α lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J. Neurosci. Res.78, 362–370 (2004).
   PubMed Web of Science ®Google Scholar
• Schillace RV, Pisenti N, Pattamanuch N et al. Lipoic acid stimulates cAMP production in T lymphocytes and NK cells. Biochem. Biophys. Res. Commun.354, 259–264 (2007).
   PubMedGoogle Scholar
• Salinthone S, Schillace RV, Marracci GH, Bourdette DN, Carr DW. Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN γ synthesis and cellular cytotoxicity in NK cells. J. Neuroimmunol.199, 46–55 (2008).
   PubMed Web of Science ®Google Scholar
• Yadav V, Marracci G, Lovera J et al. Lipoic acid in multiple sclerosis: a pilot study. Mult. Scler.11, 159–165 (2005).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hanefeld M, Ruhnau K et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia38, 1425–1433 (1995).
   PubMed Web of Science ®Google Scholar
• Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic. Res.31, 171–179 (1999).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hanefeld M, Ruhnau K et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care22, 1296–1301 (1999).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Schatz H, Conrad F, Gries F, Ulrich H, Reichel G. Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care20, 369–373 (1997).
   PubMed Web of Science ®Google Scholar
• Ruhnau K, Meissner H, Finn J et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (α-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med.16, 1040–1043 (1999).
   PubMed Web of Science ®Google Scholar
• Ametov AS, Barinov A, Dyck PJ et al. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the SYDNEY trial. Diabetes Care26, 770–776 (2003).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Reljanovic M, Mehnert H, Gries FA. α-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes107, 421–430 (1999).
   PubMed Web of Science ®Google Scholar
• van Beek TA, Montoro P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J. Chromatogr. A1216, 2002–2032 (2009).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology41, 685–691 (1991).
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol.58, 1602–1606 (2001).
   PubMed Web of Science ®Google Scholar
• Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. J. Neurol. Sci.283, 224–229 (2009).
   PubMed Web of Science ®Google Scholar
• Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol.13, 981–985 (2006).
   PubMed Web of Science ®Google Scholar
• Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry36, 297–303 (2003).
   PubMed Web of Science ®Google Scholar
• Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord.11, 230–237 (2000).
   PubMed Web of Science ®Google Scholar
• Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Hum. Psychopharmacol.9, 215–222 (1994).
   Web of Science ®Google Scholar
• Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA278, 1327–1332 (1997).
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA300, 2253–2262 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr. Alzheimer Res.2, 541–551 (2005).
   PubMedGoogle Scholar
• van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J. Clin. Epidemiol.56, 367–376 (2003).
   PubMed Web of Science ®Google Scholar
• van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am. Geriatr. Soc.48, 1183–1194 (2000).
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev.2, CD003120 (2007).
   Google Scholar
• Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev.1, CD003120 (2009).
   Google Scholar
• Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev.4, CD003120 (2002).
   PubMedGoogle Scholar
• Lovera J, Bagert B, Smoot K et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult. Scler.13, 376–385 (2007).
   PubMed Web of Science ®Google Scholar
• Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can. J. Neurol. Sci.21, 9–14 (1994).
   PubMed Web of Science ®Google Scholar
• Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch. Phys. Med. Rehabil.65, 135–138 (1984).
   PubMed Web of Science ®Google Scholar
• Lee J, Zhao YLiand X-J. Current evaluation of the milliennium phytomedicine – Ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr. Med. Chem.16, 2924–2942 (2009).
   PubMedGoogle Scholar
• Blumenthal M. Asian ginseng: potential therapeutic uses. Adv. Nurse Pract.9, 26–28 (2001).
   PubMedGoogle Scholar
• Chan TW, But PP, Cheng SW, Kwok IM, Lau FW, Xu HX. Differentiation and authentication of Panax ginseng, Panax quinquefolius, and ginseng products by using HPLC/MS. Anal. Chem.72, 1281–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Fuzzati N, Gabetta B, Jayakar K et al. Determination of ginsenosides in Panax ginseng roots by liquid chromatography with evaporative light-scattering detection. J. AOAC Int.83, 820–829 (2000).
   PubMed Web of Science ®Google Scholar
• Wang X, Sakuma T, Asafu-Adjaye E, Shiu GK. Determination of ginsenosides in plant extracts from Panax ginseng and Panax quinquefolius L. by LC/MS/MS. Anal. Chem.71, 1579–1584 (1999).
   PubMed Web of Science ®Google Scholar
• Washida D, Kitanaka S. Determination of polyacetylenes and ginsenosides in Panax species using high performance liquid chromatography. Chem. Pharm. Bull. (Tokyo)51, 1314–1317 (2003).
   PubMed Web of Science ®Google Scholar
• Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr. Cancer Ther.2, 247–267 (2003).
   PubMedGoogle Scholar
• Fulder SJ. Ginseng and the hypothalamic–pituitary control of stress. Am. J. Chin. Med.9, 112–118 (1981).
   PubMed Web of Science ®Google Scholar
• Fushimi H, Komatsu K, Isobe M, Namba T. 18S ribosomal RNA gene sequences of three Panax species and the corresponding ginseng drugs. Biol. Pharm. Bull.19, 1530–1532 (1996).
   PubMedGoogle Scholar
• Hiai S, Yokoyama H, Oura H, Yano S. Stimulation of pituitary–adrenocortical system by ginseng saponin. Endocrinol. Jpn26, 661–665 (1979).
   PubMedGoogle Scholar
• Kennedy DO, Scholey AB. Ginseng: potential for the enhancement of cognitive performance and mood. Pharmacol. Biochem. Behav.75, 687–700 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SH, Park KS. Effects of Panax ginseng extract on lipid metabolism in humans. Pharmacol. Res.48, 511–513 (2003).
   PubMed Web of Science ®Google Scholar
• Maresco A. Double-blind study of multivitamin complex supplemented with ginseng extract. Drugs Exp. Clin. Res.22, 323–329 (1996).
   PubMedGoogle Scholar
• Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int. J. Clin. Pharmacol. Res.19, 89–99 (1999).
   PubMedGoogle Scholar
• Kim E, Lovera J, Schaben L, Bourdette D, Whitham R. A single center, randomized, double-blind, placebo-controlled crossover pilot study of the effects of American ginseng on multiple sclerosis fatigue. Neurology255, A225 (2009).
   Google Scholar
• Siegel RK. Ginseng abuse syndrome. Problems with the panacea. JAMA241, 1614–1615 (1979).
   PubMed Web of Science ®Google Scholar
• Chan PC, Peckham JC, Bishop JB et al. National Toxicology Program technical report on toxicology and carcinogenesis studies of ginseng in F344/N rats and B6C3F1 mice. National Institutes of Health Publication No. 10-5909 (2009).
   Google Scholar
• Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J. Nutr.128, 2334–2340 (1998).
   PubMed Web of Science ®Google Scholar
• Koh SH, Lee SM, Kim HY et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci. Lett.395, 103–107 (2006).
   PubMed Web of Science ®Google Scholar
• Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem.78, 1073–1082 (2001).
   PubMed Web of Science ®Google Scholar
• Choi YB, Kim YI, Lee KS, Kim BS, Kim DJ. Protective effect of epigallocatechin gallate on brain damage after transient middle cerebral artery occlusion in rats. Brain Res.1019, 47–54 (2004).
   PubMed Web of Science ®Google Scholar
• Aktas O, Prozorovski T, Smorodchenko A et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-κ B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol.173, 5794–5800 (2004).
   PubMed Web of Science ®Google Scholar
• McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res.2, 673–682 (2009).
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Call TG, Zent CS et al. Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J. Clin. Oncol.27, 3808–3814 (2009).
   PubMed Web of Science ®Google Scholar
• Brown AL, Lane J, Coverly J et al. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br. J. Nutr.101, 886–894 (2009).
   PubMed Web of Science ®Google Scholar
• Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin. Nutr.27, 363–370 (2008).
   PubMed Web of Science ®Google Scholar
• Gloro R, Hourmand-Ollivier I, Mosquet B et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur. J. Gastroenterol. Hepatol.17, 1135–1137 (2005).
   PubMed Web of Science ®Google Scholar
• Pedros C, Cereza G, Garcia N, Laporte JR. [Liver toxicity of Camellia sinensis dried etanolic extract]. Med. Clin. (Barc.)121, 598–599 (2003).
   PubMed Web of Science ®Google Scholar
• Vial T, Bernard G, Lewden B, Dumortier J, Descotes J. [Acute hepatitis due to Exolise, a Camellia sinensis-derived drug]. Gastroenterol. Clin. Biol.27, 1166–1167 (2003).
   PubMed Web of Science ®Google Scholar
• Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am. J. Clin. Nutr.61, 638S–645S (1995).
   PubMed Web of Science ®Google Scholar
• Holick MF, Schnoes HK, DeLuca HF. Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc. Natl Acad. Sci. USA68, 803–804 (1971).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, DeLuca HF, Omdahl J, Holick MF. Mechanism of action of 1,25-dihydroxycholecalciferol on intestinal calcium transport. Proc. Natl Acad. Sci. USA68, 1286–1288 (1971).
   PubMed Web of Science ®Google Scholar
• Cranney A, Horsley T, O’Donnell S et al. Effectiveness and safety of vitamin D in relation to bone health. Evid. Rep. Technol. Assess. (Full Rep.)1–235 (2007).
   Google Scholar
• van den Berg H. Bioavailability of vitamin D. Eur. J. Clin. Nutr.51(Suppl. 1), S76–S79 (1997).
   PubMed Web of Science ®Google Scholar
• Adams JS, Liu PT, Chun R, Modlin RL, Hewison M. Vitamin D in defense of the human immune response. Ann. NY Acad. Sci.1117, 94–105 (2007).
   PubMed Web of Science ®Google Scholar
• Szodoray P, Nakken B, Gaal J et al. The complex role of vitamin D in autoimmune diseases. Scand. J. Immunol.68, 261–269 (2008).
   PubMed Web of Science ®Google Scholar
• Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain132, 1146–1160 (2009).
   PubMed Web of Science ®Google Scholar
• Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis: a review. J. Neuroimmunol.194, 7–17 (2008).
   PubMed Web of Science ®Google Scholar
• Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA296, 2832–2838 (2006).
   PubMed Web of Science ®Google Scholar
• Munger KL, Zhang SM, O’Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology62, 60–65 (2004).
   PubMed Web of Science ®Google Scholar
• Barnes MS, Bonham MP, Robson PJ et al. Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult. Scler.13, 670–672 (2007).
   PubMed Web of Science ®Google Scholar
• van der Mei IA, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol.254, 581–590 (2007).
   PubMed Web of Science ®Google Scholar
• Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler.11, 266–271 (2005).
   PubMed Web of Science ®Google Scholar
• Hiremath GS, Cettomai D, Baynes M et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult. Scler.15, 735–740 (2009).
   PubMedGoogle Scholar
• Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry76, 1294–1296 (2005).
   PubMed Web of Science ®Google Scholar
• Kragt J, van Amerongen B, Killestein J et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler.15, 9–15 (2009).
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Maugeri NJ, Handunnetthi L et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet.5, e1000369 (2009).
   PubMed Web of Science ®Google Scholar
• Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest.87, 1103–1107 (1991).
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Humpal-Winter J, DeLuca HF. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J. Nutr.129, 1966–1971 (2009).
   Google Scholar
• Nashold FE, Miller DJ, Hayes CE. 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol.103, 171–179 (2000).
   PubMed Web of Science ®Google Scholar
• Smolders J, Thewissen M, Peelen E et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One4, e6635 (2009).
   PubMed Web of Science ®Google Scholar
• Correa F, Docagne F, Mestre L et al. Cannabinoid system and neuroinflammation: implications for multiple sclerosis. Neuroimmunomodulation14, 182–187 (2007).
   PubMedGoogle Scholar
• Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol.9, 59 (2009).
   PubMed Web of Science ®Google Scholar
• Killestein J, Hoogervorst EL, Reif M et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology58, 1404–1407 (2002).
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil.17, 21–29 (2003).
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet362, 1517–1526 (2003).
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler.10, 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Vaney C, Heinzel-Gutenbrunner M, Jobin P et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler.10, 417–424 (2004).
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol.14, 290–296 (2007).
   PubMed Web of Science ®Google Scholar
• Swank RL, Dugan BB. The Mutliple Sclerosis Diet Book: A Low Fat Diet for the Treatment of MS. Doubleday, NY, USA (1987).
   Google Scholar
• Swank RL. Treatment of multiple sclerosis with low-fat diet. AMA Arch. Neurol. Psychiatry69, 91–103 (1953).
   PubMedGoogle Scholar
• Swank RL. Multiple sclerosis: twenty years on low fat diet. Arch. Neurol.23, 460–474 (1970).
   PubMedGoogle Scholar
• Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet336, 37–39 (1990).
   PubMed Web of Science ®Google Scholar
• Swank RL, Goodwin J. Review of MS patient survival on a Swank low saturated fat diet. Nutrition19, 161–162 (2003).
   PubMed Web of Science ®Google Scholar
• Swank RL, Grimsgaard A. Multiple sclerosis: the lipid relationship. Am. J. Clin. Nutr.48, 1387–1393 (1988).
   PubMed Web of Science ®Google Scholar
• Das UN. Is there a role for saturated and long-chain fatty acids in multiple sclerosis? Nutrition19, 163–166 (2003).
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Baier M, Park Y et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot. Essent. Fatty Acids73, 397–404 (2005).
   PubMed Web of Science ®Google Scholar
• Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol. Scand.102, 143–149 (2000).
   PubMed Web of Science ®Google Scholar
• Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case–control study in Montreal, Canada. Int. J. Epidemiol.27, 845–852 (1998).
   PubMed Web of Science ®Google Scholar
• Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J. Hum. Nutr. Diet14, 349–357 (2001).
   PubMed Web of Science ®Google Scholar
• Schwarz S, Leweling H. Multiple sclerosis and nutrition. Mult. Scler.11, 24–32 (2005).
   PubMed Web of Science ®Google Scholar